Azenta (BA3) Stock Price & Analysis
BA3 Stock Chart & Stats
- Day’s Range
- N/A
- 52-Week Range
- N/A
- Previous Close
- N/A
- Volume
- N/A
- Average Volume (3M)
- N/A
- Market Cap
- CHF 1.40B
- Enterprise Value
- CHF 881.45M
- Total Cash (Recent Filing)
- CHF 325.80M
- Total Debt (Recent Filing)
- CHF 53.97M
- Price to Earnings (P/E)
- ―
- Beta
- -0.01
- Next Earnings
- Nov 10, 2026 (Est.)
- EPS Estimate
- 0.09
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Recurring Revenue And Biorepository Momentum
A revenue base with more than half recurring provides greater visibility than project-only demand and supports repeat consumables, services, and biorepository activity. Growth in these businesses can improve customer retention and make future revenue less dependent on individually timed capital projects.
Conservative Balance Sheet
Very low leverage and a substantial equity cushion reduce refinancing and solvency pressure while preserving flexibility for investment, integration, or operational needs. This financial foundation can help Azenta absorb uneven earnings and pursue strategic initiatives without relying heavily on additional debt.
Expanded GENEWIZ Technology Platform
The Elegen and SynPlexity transactions broaden GENEWIZ’s capabilities across DNA synthesis, gene assembly, and large-scale screening. These additions can strengthen Azenta’s position in next-generation biologics discovery and support demand from increasingly AI-driven biological design workflows.
Bears Say
Persistent Unprofitability
Negative operating earnings and a deeply negative net margin show that Azenta is not yet consistently converting revenue into profit. Until operating costs and other charges are better controlled, growth may add limited earnings value and internal funding capacity will remain constrained.
Gross-margin Pressure And Remediation Costs
Declining gross margin in Sample Management Solutions, combined with remediation spending, directly pressures profitability and cash conversion. If automated-store quality and fixed-cost absorption issues persist, the company may need continued investment before this business can deliver sustainably higher margins.
Multiomics Restructuring And Execution Disruption
Closing laboratories and reducing the workforce may eventually improve efficiency, but the transition creates near-term execution risk and substantial charges. Changes to the laboratory footprint can also complicate service continuity, employee retention, and customer relationships while the segment is being reshaped.
BA3 FAQ
What is Azenta’s market cap?
When is Azenta’s upcoming earnings report date?
How were Azenta’s earnings last quarter?
Is Azenta overvalued?
Does Azenta pay dividends?
What is Azenta’s EPS estimate?
How many shares outstanding does Azenta have?
What happened to Azenta’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Azenta?
What is the TipRanks Smart Score and how is it calculated?
Azenta Stock Smart Score
Company Description
Azenta
Azenta, Inc. is a global leader specializing in advanced solutions for the discovery, handling, and preservation of life science samples. The company's operations span across North America, Europe, Asia Pacific (including China), and other international markets. Its business is structured into two main reportable segments: Life Sciences Products and Life Sciences Services. The Life Sciences Products division supplies sophisticated automated systems for the cold storage of chemical compounds and biological specimens. This segment also provides crucial equipment for sample preparation and manipulation, along with various consumables and specialized instruments that empower customers to effectively manage samples throughout their entire research and development workflows. Conversely, the Life Sciences Services segment offers a comprehensive suite of programs for sample management, integrated cold chain logistics, cutting-edge informatics, and a range of sample-centric laboratory services. These offerings are vital for propelling scientific research and accelerating drug development. Key services include secure sample banking, advanced genomic sequencing, gene synthesis, laboratory processing, detailed laboratory analysis, biospecimen acquisition, and other essential support functions. Azenta caters to a diverse client base within the life sciences sector, encompassing pharmaceutical companies, biotechnology firms, biorepositories, and academic or private research institutions. Established in 1978, the company, originally known as Brooks Automation, Inc., officially became Azenta, Inc. in December 2021. Its corporate headquarters are located in Chelmsford, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Martin D. Madaus
- Employees
- 2,900
- Website
- www.azenta.com
- Address
- 200 Summit Drive, Burlington, MA, 01803, US
Azenta (BA3) Earnings & Revenues
BA3 Company Deck
BA3 Earnings Call
Earnings Call SentimentNeutral
The call reflected a cautious but constructive tone: the company delivered a better-than-expected quarter with solid organic revenue growth (9%), sequential profitability improvement (adjusted EBITDA margin up ~610 bps sequentially) and progress on strategic initiatives (AI-enabled biorepository deployment, modular stores, UKBC integration, and B Medical divestiture). However, meaningful near-term headwinds remain — notably gross margin pressure (overall and in Sample Management Solutions), quality remediation costs ($5M–$6M expected), ongoing Sanger secular decline, negative quarterly free cash flow, and a difficult Q4 comp. Management emphasized disciplined execution and a measured outlook. Overall, positives around execution and a stronger outlook are balanced by persistent margin and demand uncertainties.
View all CH:BA3 earnings summaries